Biomarin Pharmaceutical (BMRN) Free Cash Flow (2009 - 2026)

Biomarin Pharmaceutical (BMRN) has 18 years of Free Cash Flow data on file, last reported at $199.7 million in Q1 2026.

• Quarterly Free Cash Flow rose 26.71% year-over-year to $199.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $767.1 million (up 22.89% YoY) and the FY2025 annual result came in at $725.0 million, up 48.73% from the prior year.
• Free Cash Flow climbed to $199.7 million in Q1 2026, from $58.9 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $319.9 million in Q3 2025 to a low of -$126.3 million in Q4 2022.
• A 5-year average of $93.8 million and a median of $94.2 million in 2022 frame the typical range for Free Cash Flow.
• Annual changes were most pronounced in 2022 — Free Cash Flow slumped 2629.3% — and 2025, when it surged 655.38%.
• Tracing BMRN's Free Cash Flow over 5 years: stood at -$126.3 million in 2022, then surged by 150.75% to $64.1 million in 2023, then jumped by 159.09% to $166.1 million in 2024, then tumbled by 64.53% to $58.9 million in 2025, then soared by 238.97% to $199.7 million in 2026.
• The last three Free Cash Flow figures came in at $199.7 million (Q1 2026), $58.9 million (Q4 2025), and $319.9 million (Q3 2025), per Business Quant data.